Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in ACAD — Acadia Pharmaceuticals Inc

CIK 1423053 MIAMI, FL
Back to ACAD Full portfolio

Position in ACAD

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$13,862,637
-$22,662,192 QoQ
Shares Held
622,760
-54.5% QoQ
Ownership
0.364%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
24 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in ACAD Over Time

Shares Held

Position Value (USD)

Derivatives in ACAD

reported options exposure · as of Mar 31, 2026
CallValue
$445,200
CallShares
20,000
PutValue
$353,934
PutShares
15,900

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. ACAD ranks #79 (0.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 2,182,571 $356,894,009
2 ONC
BeOne Medicines Ltd.
 1,032,298 $306,561,536
3 BMRN
Biomarin Pharmaceutical Inc
 4,512,634 $254,918,694
4 JAZZ
Jazz Pharmaceuticals plc
 1,259,444 $238,097,887
5 MDGL
Madrigal Pharmaceuticals, Inc.
 453,843 $237,573,195
6 BBIO
BridgeBio Pharma, Inc.
 3,173,940 $235,696,783
7 TERN
Terns Pharmaceuticals, Inc.
 3,218,810 $169,695,662
8 PTGX
Protagonist Therapeutics, Inc
 1,551,900 $163,570,260

All Filings in ACAD

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $353,934 15,900
2026-03-31 $13,862,637 622,760
2026-03-31 $445,200 20,000
2025-12-31 $694,460 26,000
2025-12-31 $36,524,829 1,367,459
2025-12-31 $320,520 12,000
2025-09-30 $1,683,726 78,900
2025-09-30 $6,903,916 323,520
2025-09-30 $1,995,290 93,500
2025-06-30 $64,983,852 3,012,696
2025-06-30 $1,145,367 53,100
2025-06-30 $1,404,207 65,100
2025-03-31 $1,320,495 79,500
2025-03-31 $4,894,302 294,660
2025-03-31 $1,001,583 60,300
2024-12-31 $1,262,480 68,800
2024-12-31 $1,701,045 92,700
2024-12-31 $6,199,822 337,865
2024-09-30 $1,230,400 80,000
2024-09-30 $2,577,102 167,562
2024-09-30 $470,628 30,600
2024-06-30 $1,066,000 65,600
2024-06-30 $1,457,625 89,700
2024-06-30 $10,623,729 653,768
2024-03-31 $1,503,237 81,300
2024-03-31 $10,525,579 569,258
2024-03-31 $2,647,768 143,200
2023-12-31 $2,536,110 81,000
2023-12-31 $3,559,947 113,700
2023-12-31 $4,791,494 153,034
2023-09-30 $1,704,712 81,800
2023-09-30 $4,251,360 204,000
2023-09-30 $112,723 5,409
2023-06-30 $555,663 23,201
2023-06-30 $404,755 16,900
2023-06-30 $716,105 29,900
2023-03-31 $685,048 36,400
2023-03-31 $1,951,313 103,683
2023-03-31 $651,172 34,600
2022-12-31 $3,498,547 219,758
2022-12-31 $866,048 54,400
2022-12-31 $1,951,792 122,600
2022-09-30 $1,145,200 70,000
2022-09-30 $6,695,803 409,279
2022-09-30 $2,422,916 148,100
2022-06-30 $4,401,716 312,400
2022-06-30 $6,441,948 457,200
2022-06-30 $4,217,094 299,297
2022-03-31 $10,098,237 416,938
2022-03-31 $3,180,086 131,300

Report a Problem

Category
Description
Email (optional, for follow-up)